SION - NASDAQ
Sionna Therapeutics, Inc.
$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
At a Glance
Live SnapshotSionna Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Sionna Therapeutics, Inc. Balance Sheet
SION • NASDAQ
| Sionna Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
58.5M | 37.8M | 38.5M | 54.8M | |
177.4M | 109.8M | 0.0 | 27.8M | |
235.9M | 147.5M | 38.5M | 82.6M | |
5.5M | 3.5M | 686K | 1.2M | |
241.4M | 151M | 39.2M | 83.8M | |
NON-CURRENT ASSETS | ||||
9.2M | 10.3M | 11.7M | 2.6M | |
0.0 | 20.5M | 0.0 | 0.0 | |
75.4M | 4M | 1M | 962K | |
84.5M | 34.8M | 12.7M | 3.5M | |
326M | 185.8M | 51.9M | 87.4M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
769K | 1.2M | 719K | 557K | |
769K | 1.2M | 719K | 557K | |
0.0 | 5.2M | 3.5M | 5.7M | |
1.3M | 1.1M | 728K | 0.0 | |
9.7M | 3M | 3.1M | 2M | |
11.7M | 10.4M | 8M | 8.3M | |
NON-CURRENT LIABILITIES | ||||
0.0 | 330.4M | 149M | 149M | |
7.4M | 339M | 158.8M | 149M | |
8.7M | 9.7M | 10.5M | 0.0 | |
19.1M | 349.5M | 166.8M | 157.3M | |
SHAREHOLDERS' EQUITY | ||||
326M | 330.4M | 149M | 149M | |
45K | 5K | 2K | 2K | |
562.6M | 17M | 4.5M | 2.2M | |
-256.4M | -181.1M | -119.4M | -72.1M | |
540K | 368K | 0.0 | -16K | |
0.0 | -330.4M | -149M | -149M | |
306.8M | -163.7M | -114.9M | -69.9M | |
306.8M | -163.7M | -114.9M | -69.9M | |
SUMMARY | ||||
326M | 185.8M | 51.9M | 87.4M | |
177.4M | 130.3M | 0.0 | 27.8M | |
8.7M | 9.7M | 10.5M | 0.0 | |
-49.8M | -28M | -28M | -54.8M | |
44,628,787 | 44,628,787 | 44,628,787 | 44,628,787 |
SEC Filings
SION - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 11, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 11, 2025 | August 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 13, 2025 | June 12, 2025 | 2025 |
Related Guides
Continue your SION research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.